The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.

The FDA has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

For patients at high cardiovascular risk with overweight/obesity, semaglutide is associated with reduced burden of total hospital admissions.

HealthDay News — The Pooled Cohort Equations (PCE) cardiovascular risk score stratifies risk for multiple ocular diseases, according to a study published online Dec. 29 in Ophthalmology.

Post hoc trial findings support aprocitentan’s potential cardiovascular and kidney-protective effects in patients with chronic kidney disease (CKD) with resistant hypertension.

Novo Nordisk announced the availability of Wegovy tablets, the first oral GLP-1 receptor agonist for weight loss and CV risk ...

For patients with hypertension, initiating treatment with an ARB is associated with the best long-term class persistence.

Management of mitochondrial-related heart disease relies on multidisciplinary care and symptom control, as targeted gene-editing therapies are limited.

Early intensive BP control significantly reduces cardiovascular risk in older patients compared with delayed initiation of treatment.

In 2025, the number of all students enrolled in medical school reached 100,723 — a significant milestone for the future of health care. After a slight dip in recent years, overall applications rose ...

Reaching prediabetes remission is linked to a decades-long benefit, with risk for cardiovascular death or hospitalization for HF cut in half.

Carotid stenosis severity serves as a predictor for cognitive impairment independent of white matter lesions and traditional vascular risk factors.